Novel disease-specific promoters for use in gene therapy for Parkinson's disease.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Gene therapy is a promising therapeutic tool for Parkinson's disease (PD), but there is a lack of evaluated cell specific promoters that are relevant for the disease. We have chosen PD relevant promoter candidates for gene therapy vectors based on either previous studies; Drd1a, Drd2 and pDyn, or from a microarray study on parkinsonian patients; ACE, DNAJC3, GALNS, MAP1a and RNF25. These candidates have been evaluated in rat striatum to determine their suitability for use in cell specific vectors. The promoters had a neuronal specificity of 91-100%. The efficiency of the promoters was variable, but RNF25, DNAJC3 and MAP1a were comparable to widely used ubiquitous promoters. MAP1a was also affected by dopamine depletion.

Detaljer

Författare
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Neurovetenskaper

Nyckelord

Originalspråkengelska
Sidor (från-till)29-34
TidskriftNeuroscience Letters
Volym530
Utgåva nummer1
StatusPublished - 2012
PublikationskategoriForskning
Peer review utfördJa

Relaterad forskningsoutput

Erika Elgstrand, 2013, Department of Experimental Medical Science, Lund Univeristy. 116 s.

Forskningsoutput: AvhandlingDoktorsavhandling (sammanläggning)

Visa alla (1)